Streetbeat News

Stock Prices

VVOS

Vivos Therapeutics shares rose following Ascendiant Capital's decision to maintain a Buy rating and increase the price target from $6.4 to $6.6.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 7:33 pm

AGAE

Allied Gaming & Entertainment reported a year-over-year decrease in Q2 financial results, leading to a decline in its share price.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 7:32 pm

EBC

Eastern Bankshares (NYSE:EBC) has seen a 46.5% decrease in its short percent of float, now at 1.91%. This is lower than its peers' average of 5.61%. The decrease in short interest may indicate a more bullish sentiment towards the stock.

Portfolio Pulse from Benzinga Insights

August 20, 2024 | 7:30 pm

PGR

Progressive's short interest has increased by 7.5%, with 5.03 million shares sold short, representing 0.86% of its float. This is below the peer group average of 2.13%. The rise in short interest may indicate bearish sentiment, but it doesn't guarantee a price drop.

Portfolio Pulse from Benzinga Insights

August 20, 2024 | 7:30 pm

MCHP

Microchip Technology (NASDAQ:MCHP) has outperformed the market over the past 10 years with an average annual return of 12.93%, resulting in a $100 investment growing to $338.13. The article highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

August 20, 2024 | 7:30 pm

TOVX

Theriva Biologics (NYSE:TOVX) has seen a 58.82% increase in its short percent of float, now at 0.27% of available shares. This rise in short interest suggests a bearish sentiment among investors, although it remains below the peer group average of 6.59%.

Portfolio Pulse from Benzinga Insights

August 20, 2024 | 7:30 pm

RMD

ResMed (NYSE:RMD) has significantly outperformed the market over the past decade, with an annualized return of 15.63%. A $1000 investment in ResMed 10 years ago would now be worth $4,326.72, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 20, 2024 | 7:30 pm

SPRC

SciSparc Ltd. (NASDAQ:SPRC) has enrolled the first five patients in its clinical trial for a CBD-based treatment for autism spectrum disorder (ASD) in children. The trial, conducted at Soroka Medical Center in Israel, aims to assess the efficacy and safety of SciSparc's proprietary SCI-210 drug. The company plans to enroll 60 subjects and eventually sell the treatment in Israel and other countries.

Portfolio Pulse from Jelena Martinovic

August 20, 2024 | 7:28 pm

BSAC

CIB

Goldman Sachs upgraded Banco Santander-Chile (BSAC) from Sell to Neutral, expecting strong earnings momentum and a rebound in return on equity. Conversely, Bancolombia (CIB) was downgraded from Neutral to Sell due to weak earnings momentum and economic pressures in Colombia.

Portfolio Pulse from Michael Juliano

August 20, 2024 | 7:27 pm

WBUY

Webuy shares surged following the announcement of $2.9 million in revenue generated over three days at the 2024 NATAS Fair.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 7:26 pm